ArticleToxins2026
Effects of Chlorogenic Acid on Deoxynivalenol (DON)-Induced Ferroptosis in Porcine Alveolar Macrophages.
Article in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deoxynivalenol (DON) is a mycotoxin commonly found in food crops and animal feed worldwide. Its pronounced toxicity in pigs poses a serious risk to the swine industry and to human health. This study focused on two central features of ferroptosis-iron metabolism and lipid peroxidation-and examined how chlorogenic acid (CGA) affects DON-induced ferroptosis in porcine alveolar macrophages (PAMs) via cell-based assays and oxidative lipid metabolomics. These findings show that DON disrupts intracellular iron homeostasis by altering iron-handling proteins (upregulating TFR1 and DMT1 and downregulating FPN1), which may lead to iron overload. Concurrently, DON impairs the GPX4 antioxidant axis (downregulating GPX4, SLC3A2, SLC7A11, and GCLC) and increases ROS, and exposure led to a significant increase in numerous oxidized lipid metabolites, consistent with elevated lipid peroxidation, culminating in ferroptosis in PAMs. CGA mitigates these effects by restoring iron homeostasis and reestablishing GPX4 axis function, thereby reducing oxidative stress. Moreover, CGA suppresses lipid peroxidation pathways, notably linoleic acid oxidation metabolism. In conclusion, CGA protects PAMs and mitigates the proferroptotic effects of DON.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.